ISOFOL MEDICAL SHARE ISSUE OVERSUBSCRIBED, SECURING OVER SEK 39 MILLION TO STRENGTHEN THE ONGOING PHASE II CLINICAL DEVELOPMENT PROGRAM OF MODUFOLIN®

About Isofol

Isofol Medical AB (publ) is a biotech company within the field of oncology developing arfolitixorin, primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer).